Raptor Pharmaceutical Corp. To Present At The Cowen And Company 33rd Annual Health Care Conference

NOVATO, Calif., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the Cowen and Company 33 rd Annual Health Care Conference in Boston at the Marriott Copley Place. Raptor's presentation will take place on Tuesday, March 5, 2013 beginning at 8:40 a.m. ET/5:40 a.m. PT.

A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com .

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical is an emerging biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company is currently focused on the development of its first product candidate, RP103 (delayed-release oral cysteamine bitartrate), as a potential treatment for nephropathic cystinosis, a rare genetic disorder. In addition to cystinosis, the company is also testing RP103 for the potential treatment of non-alcoholic steatohepatitis, or NASH, a metabolic liver disorder, and Huntington's Disease, or HD, a neurodegenerative disorder.

For additional information, please visit www.raptorpharma.com .

The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180
CONTACT: Georgia Erbez         Chief Financial Officer         Raptor Pharmaceutical Corp.         (415) 382-8111 x204         gerbez@raptorpharma.com

company logo

If you liked this article you might like

Drug Win for Depomed Could Be Hurdle for Starboard

Arbor and Purdue Seen as Likely Bidders for DepoMed

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

Fed Dove Brainard Pushes Stocks Into Rally Mode

Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar